LEAWOOD, Kan., June 25, 2021 (GLOBE NEWSWIRE) — CrossFirst Bankshares, Inc. (Nasdaq: CFB) will release its second quarter 2021 results on Thursday, July 22, 2021, with a press release issued after market close.
CrossFirst’s management team will hold a conference call and webcast to discuss second quarter 2021 results on Thursday, July 22, 2021, at 4 p.m. Central time / 5 p.m. Eastern time.
Investors, news media, and other participants should register for the call or audio webcast at https://investors.crossfirstbankshares.com, participants may dial into the call toll-free at (877) 621-5851 from anywhere in the U.S. or (470) 495-9492 internationally, using conference ID no. 9690426.  Participants are encouraged to dial into the call or access the webcast approximately 10 minutes prior to the start time.
A replay of the webcast will be available on the company website.  A replay of the conference call will be available two hours following the close of the call until July 29, 2021, accessible at (855) 859-2056 with conference ID no. 9690426.
ABOUT CROSSFIRST
CrossFirst Bankshares, Inc. (Nasdaq: CFB) is a Kansas corporation and a registered bank holding company for its wholly-owned subsidiary CrossFirst Bank, which is headquartered in Leawood, Kansas. CrossFirst Bank has eight full-service banking offices primarily along the I-35 corridor in Kansas, Missouri, Oklahoma and Texas.
Investor Relations/Media Contact:
Matt Needham
CrossFirst Bankshares, Inc.
913-312-6822Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
matt@crossfirst.com
- Icahn Enterprises L.P. Investor Notification: Kessler Topaz Meltzer & Check, LLP Announces July 10, 2023 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Icahn Enterprises L.P. - June 3, 2023
- FOX, FOXA INVESTOR NEWS: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fox Corporation Investors to Inquire About Class Action Investigation – FOX, FOXA - June 3, 2023
- Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 - June 3, 2023